Latest News

September 14, 2023
September 14, 2023
Categories

Brown University’s Jon Steingrimsson named Associate Group Statistician

Do you like it?
Read more
September 8, 2023
September 8, 2023
Categories

European Urology Focus publishes an update on the EA8212 (BRIDGE) trial for early bladder cancer

Do you like it?
Read more
September 8, 2023
September 8, 2023
Categories

Deadline Extended: Radiation oncologists and trainees, apply for travel funds for the Fall 2023 Group Meeting by September 15

Do you like it?
Read more
August 25, 2023
August 25, 2023
Categories

The July/August 2023 News from ECOG-ACRIN blog is now available

Do you like it?
Read more
August 9, 2023
August 9, 2023
Categories

Attention CRAs: Travel funds are available for the Fall 2023 Group Meeting (apply now)

Do you like it?
Read more
Load more

Tweets

ECOG-ACRIN Cancer Research Group Follow

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

eaonc
eaonc ECOG-ACRIN Cancer Research Group @eaonc ·
10h

EA9152 is a phase 1b/2 study of venetoclax in combination with vincristine sulfate in patients with relapsed or refractory T-cell or B-cell #ALL. September is #BloodCancerAwarenessMonth🩸, learn more about this important #leukemia trial: https://bit.ly/EA9152 cc: @SelinaLugerMD

Reply on Twitter 1707111023268745434 Retweet on Twitter 1707111023268745434 Like on Twitter 1707111023268745434 Twitter 1707111023268745434
eaonc ECOG-ACRIN Cancer Research Group @eaonc ·
12h

Are you a teen or young adult #lymphoma survivor that has finished treatment? If so, you may be eligible to participate in the @cancergenomics_ study that could make a positive impact on the #AYA #cancer community. Learn more: https://bit.ly/eaq211-study #AYACancer #AYACSM

Reply on Twitter 1707093022721097797 Retweet on Twitter 1707093022721097797 Like on Twitter 1707093022721097797 1 Twitter 1707093022721097797
eaonc ECOG-ACRIN Cancer Research Group @eaonc ·
13h

EA5163/S1709/INSIGNA, led by @HosseinBorghaei of @FoxChaseCancer and @Annechiangmd of @YaleCancer, is a randomized phase III study treating patients w/ stage IV non-squamous non-small cell lung cancer. More: https://bit.ly/ea5163insigna #lcsm #nsclc cc: @lcrf_org, @GO2forLungCancr

Reply on Twitter 1707077863382344150 Retweet on Twitter 1707077863382344150 Like on Twitter 1707077863382344150 Twitter 1707077863382344150
Load More

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Home

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Home
56

Active Clinical Trials

Home
1300

Participating Institutions

Home
67

International Sites

Home
15000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).

ECOG-ACRIN Cancer Research Group